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Epigenetics and Non-Communicable Diseases 
Gemma C Sharp, Caroline L Relton 
 
Noncommunicable diseases (NCDs), primarily cardiovascular disease, cancer, chronic 
respiratory disease and diabetes, kill more than 38 million people each year, making them by 
far the leading cause of death in the world1. They develop due to an interplay of genetic, 
lifestyle and environmental factors, but many NCDs are considered preventable because the 
most important risk factors, such as tobacco use, alcohol use and obesity, are modifiable1. 
Nevertheless, the prevalence of NCDs is increasing, and ongoing research hopes to inform 
effective strategies to predict, prevent and treat. This includes research into the role and 
utility of epigenetic mechanisms, either as an important determinant of NCDs (where 
causality is important) or as useful markers to help predict their occurrence and/or their 
consequences (where causality is not important). 
 
Epigenetics as a determinant of NCDs: where causality is important 
Since epigenetic changes can occur in response to external stimuli, can remain stable over 
time and can lead to long-term changes in gene expression and pathological dysfunctions, it 
is plausible that epigenetics might contribute to the onset of NCDs. Much of the support for 
this hypothesis comes from animal studies, which have shown environmentally-induced 
epigenetic changes within key tissues that are also associated with later-life health 
consequences. For example, a mouse study published 10 years ago showed that offspring of 
dams fed a low-protein diet during pregnancy had lower DNA methylation of the angiotensin 
receptor gene and this was associated with higher blood pressure2. More recently, human 
studies have found epigenome-wide associations between DNA methylation and several 
NCDs, including a wide range of cancers3, asthma4, obesity5 and type 2 diabetes6.  
 
While these studies might suggest that epigenetic mechanisms contribute to the onset of 
NCDs, there are two main potential limitations that should be considered before results from 
human observational studies are interpreted in this way. Firstly, the association between the 
NCD and epigenetic mechanism could be confounded by environmental or genetic factors or 
by cellular composition of the biological sample. Secondly, the association could be explained 
via a reverse causal pathway, that is, the NCD caused the epigenetic changes rather than the 
other way around.  
 
The field in general needs better causal evidence to underpin the mechanistic link between 
epigenetic variation and NCDs7. Fortunately, there are a number of strategies that can be 
applied to help infer causality in studies of epigenetics and NCDs. Some of these are unique 
to epigenetic epidemiological studies. For example, integrating epigenomic data with 
genomic and transcriptomic data from the same biological samples to allow a more 
comprehensive investigation of potential causal pathways to NCDs. Additionally, measuring 
epigenetics in purified cells, or adjusting for estimated or measured cellular heterogeneity in 
mixed cell population samples can help to lessen the influence of cell types confounding 
associations7.  
Other strategies to improve causal inference are already widely used in non-epigenetic 
observational studies8. These include using a longitudinal study design (rather than a cross-
sectional case-control design) where epigenetic data are collected prior to NCD onset, thus 
circumventing issues with reverse causation. There are many examples of epigenome-wide 
studies assessing associations between DNA methylation in neonatal cord blood and 
emergence of NCDs in childhood, for example, one study found associations between cord 
blood DNA methylation and cardiovascular risk (increased heart rate) at age 99. 
Another strategy is to seek replication of results in an independent sample to provide 
confidence that the identified associations are reproducible and not spurious. A growing 
number of consortia are emerging to help facilitate replication and meta-analysis between 
cohorts with epigenetic data10. Stronger evidence for a causal association can be provided by 
comparing associations across cohorts with different confounding structures. For example, 
an association between breastfeeding and childhood obesity and high blood pressure that 
was present in a UK cohort (high-income) was not present in a Brazilian cohort (low- or 
middle-income), providing evidence for confounding by socioeconomic status11. Although we 
are not aware of this approach having been used in studies of the epigenetics of NCDs, there 
is certainly scope to do so. In order to control for the large effect of genetics on epigenetics, 
co-twin designs can be useful. These compare epigenetic modifications in monozygotic twins 
discordant for an NCD to find associations between epigenetic and disease state while 
controlling for genetics. Several examples of this approach being applied to study epigenetic 
causes of NCDs are described elsewhere12. One example is a study of 50 twin pairs discordant 
for major depressive disorder, which found differences in whole blood DNA methylation13. 
Another causal inference technique that can be used in epigenetic epidemiological studies is 
the negative control design. For example, we compared the association between cord blood 
DNA methylation and maternal BMI to that of paternal BMI to help infer whether the 
apparent effect of maternal BMI on offspring DNA methylation is causal or better explained 
by shared genetic or environmental factors14,15. This approach is useful for drawing inferences 
about factors causing epigenetic changes, which might mediate associations with NCDs. 
Finally, Mendelian randomization (MR)16 is a useful causal inference technique that is 
beginning to be applied to study the role of epigenetics in the development of NCDs. This 
approach involves using genetic variants robustly associated with exposures to infer causality. 
The genetic variant serves as a proxy for the exposure, but crucially, any association between 
the genetic variant and the outcome is not subject to various confounders of the exposure-
outcome association. Since the genetic variant cannot be directly influenced by the outcome, 
MR also helps combat issues with reverse causation17,18. The approach can be used to study 
the epigenetics of NCDs by finding genetic variants near and robustly associated with 
epigenetic marks and assessing the association between these variants and the NCD. For 
example, recent studies have used MR to show that DNA methylation at specific loci may be 
causally associated with obesity, with more evidence of an effect of obesity on DNA 
methylation than the other way around5,14,19. To provide the best evidence for a mechanistic 
role of epigenetics in causing NCDs, several of the previously discussed strategies should be 
combined. 
 
Epigenetics as a predictor of NCDs and their consequences: where causality is not 
important 
Even if epigenetics does not play a causal role in NCD development, there is still great value 
in studying associations between epigenetics, NCDs, their risk factors and their consequences. 
Epigenetic information ‘captures’ information on historical exposure and underlying genetics, 
and to this end it can be used to improve understanding of the (non-epigenetic) aetiologies 
of NCDs20. For example, recent multi-cohort studies have shown that DNA methylation data 
can be a powerful predictor of alcohol consumption21 and prenatal tobacco exposure22. These 
epigenetic predictors can be used as an alternative to self-report questionnaire data, or 
where such data are lacking, to assess associations between these risk factors and NCDs. One 
of the advantages of epigenetic predictors over self-report data is that they are less prone to 
measurement error introduced by reporting bias. Clinically, such predictors could be useful 
biomarkers to identify individuals at high risk of developing certain NCDs and targeting 
preventative strategies.  
 
Additionally, studies such as the recent Mendelian randomization studies of adiposity5,14,19 
demonstrate that NCDs themselves can alter epigenetics and may provide insight into 
downstream consequences of these diseases. This raises the possibility that epigenetics could 
be useful in diagnosing NCDs before development of any clinical symptoms, and/or aiding 
prognosis or stratification of individuals with NCDs for certain treatment options. 
 
Conclusion 
In conclusion, appropriate interpretations of well-designed epigenetic studies offer the 
opportunity to improve our understanding of the aetiology of NCDs and their outcomes, 
which will help inform development of better strategies to predict, prevent and treat them. 
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